甲磺酸阿帕替尼治疗二线化疗失败上皮性卵巢癌的疗效分析

目的:探讨甲磺酸阿帕替尼治疗二线化疗失败上皮性卵巢癌(epithelial ovarian cancer,EOC)患者的疗效与安全性。方法:收集2017年9月至2018年11月46例天津医科大学肿瘤医院收治的二线化疗失败的复发性EOC患者的临床资料,分析甲磺酸阿帕替尼的疗效及治疗相关的不良事件,并评估其安全性。结果:46例患者的中位随访时间为12个月,中位总生存(overall survival,OS)时间为6(2~15)个月。客观缓解率(objective response rate,ORR)为26.1%(12/46),疾病控制率(disease control rate,DCR)为86.9%(40/46)。46例患者中30例(65.2%)出现不良反应,主要为1~2级,最常见的治疗相关不良反应为高血压占39.1%(18/46),手足皮肤综合征占30.4%(14/46),仅1例患者出现3级治疗相关性高血压,所有患者的1、2级不良事件均能迅速缓解,且甲磺酸阿帕替尼治疗后患者耐受性良好。结论:甲磺酸阿帕替尼对于二线化疗失败的EOC患者可能是一种安全且有效的治疗选择,但仍需开展大规模的临床试验进一步研究。

Evaluation of efficacy and safety of apatinib for patients with recurrent epithelial ovarian cancer

  Objective  To assess the efficacy and safety of apatinib for patients with epithelial ovarian cancer (EOC) who had failed in second-line chemotherapy.  Methods  The clinical data of 46 patients with recurrent EOC who had failed in second-line chemotherapy and were admitted to the Cancer Hospital of Tianjin Medical University from September 2017 to November 2018 were collected. The treatment efficacy of apatinib was evaluated, and treatment-related adverse events (AEs) were recorded to evaluate its safety.  Results  A total of 46 eligible patients were enrolled. The median follow- up time was 12 months. The median overall survival (OS) was 6 months (range 2-15 months). The objective response rate (ORR) was 26.1% (12/46 patients), and the disease control rate (DCR) was 86.9% (40/46 patients). AEs occurred in 30 patients (65.2%), and were mainly of grade 1-2. The most common treatment-related AEs were hypertension (39.1%) and hand-foot-skin syndrome (30.4%); only one patient experienced grade 3 treatment-related hypertension. All grade 1-2 AEs could be recovered rapidly and well-tolerated after treatment with medication.  Conclusions  Apatinib may be a safe and effective option for patients with advanced EOC who had failed in second-line chemotherapy. Further Studies are warranted in large-scale clinical trials.